Cangene was 61% owned by Canadian pharmaceutical giant Apotex and was publicly listed on the TSX under the symbol CNJ.
[6] Development of the new IVIG product was subsequently cancelled in 2012, representing a strategic turn away from R&D toward marketing in an attempt to return to profitability.
[1] Decline in profitability had come in part due to decreased cash flow from a US$500,000,000 bioterrorism-related program of work with the U.S. Biomedical Advanced Research and Development Authority.
[1] In 2013, the company purchased rights to development and commercialization of three drug candidates, recombinant blood clotting factors VIIa, VIII and IX, the latter of which is in clinical trials.
[5] At the time, the company was in the process of expanding its sales force and shifting focus from contract manufacturing to a "strategy to optimize our commercial assets.
[2][10] The contract manufacturing subdivision, Celegene bioPharma, maintains facilities in Baltimore, Maryland, United States.